JNJ Shares Tumble After Reporting Vaccine Effectiveness

Johnson & Johnson, the biggest pharmaceutical company in the world, has just released the first round of results from its Phase 3 COVID-19 vaccine trials, and they are disappointing.

They showed that the vaccine is only 66% effective at preventing moderate and severe COVID-19 (and that's excluding mild cases of the virus), which is less than Moderna, Pfizer, AstraZeneca, and others in the west.

However, western media like the FT highlighted the fact that the vaccine is, at the very least, still 57% effective against the South African variant - which is...not exactly reassuring.

The vaccine showed some protection against the 501. V2 variant, which first emerged in South Africa, although efficacy was 57 per cent in trials conducted there. The jab showed an efficacy rate of 72 per cent in the US, and 66 per cent in Latin America. Alex Gorsky, J&J’s chief executive, called the results a “critical milestone”. The company intends to file for a US emergency use authorisation in early February and, if granted, will immediately be able to ship vaccines. “Our goal all along has been to create a simple, effective solution for the largest number of people possible, and to have maximum impact to help end the pandemic,” he said.

The FT also noted that the trial results for JNJ aren't exactly comparable to other vaccines. It also noted that the vaccine doesn't require cold temperatures, and can be delivered in a single dose, all of which are advantages over vaccines produced by rivals like Pfizer and Moderna.

Chief Scientific Officer Paul Stoffels added that "a one-shot vaccine is considered by the World Health Organization to be the best option in pandemic settings, enhancing access, distribution, and compliance."

That's critical since the trial data released last night by Novavax showed that the US OWS-backed vaccine wasn't nearly as effective against the mutated virus than the version in the UK.

1 2
View single page >> |

Disclosure: Copyright ©2009-2021 ZeroHedge.com/ABC Media, LTD; All Rights Reserved. Zero Hedge is intended for Mature Audiences. Familiarize yourself with our legal and use policies every ...

more
How did you like this article? Let us know so we can better customize your reading experience.

Comments

Leave a comment to automatically be entered into our contest to win a free Echo Show.